S&P 500   3,138.65 (+0.20%)
DOW   27,877.28 (-0.02%)
QQQ   204.39 (+0.24%)
AAPL   269.94 (+0.54%)
FB   200.74 (-0.06%)
MSFT   150.41 (-0.48%)
GOOGL   1,343.13 (+0.02%)
AMZN   1,743.17 (+0.23%)
CGC   20.66 (+2.84%)
NVDA   215.42 (+0.67%)
MU   48.65 (+2.51%)
BABA   201.73 (+0.64%)
GE   11.08 (+0.54%)
TSLA   354.78 (+1.70%)
T   38.11 (+0.13%)
AMD   39.29 (-0.41%)
ACB   2.57 (+1.98%)
F   9.10 (+0.33%)
PRI   135.17 (-0.08%)
NFLX   296.89 (+1.29%)
BAC   33.57 (+0.12%)
GILD   67.63 (+0.82%)
DIS   147.71 (+1.10%)
S&P 500   3,138.65 (+0.20%)
DOW   27,877.28 (-0.02%)
QQQ   204.39 (+0.24%)
AAPL   269.94 (+0.54%)
FB   200.74 (-0.06%)
MSFT   150.41 (-0.48%)
GOOGL   1,343.13 (+0.02%)
AMZN   1,743.17 (+0.23%)
CGC   20.66 (+2.84%)
NVDA   215.42 (+0.67%)
MU   48.65 (+2.51%)
BABA   201.73 (+0.64%)
GE   11.08 (+0.54%)
TSLA   354.78 (+1.70%)
T   38.11 (+0.13%)
AMD   39.29 (-0.41%)
ACB   2.57 (+1.98%)
F   9.10 (+0.33%)
PRI   135.17 (-0.08%)
NFLX   296.89 (+1.29%)
BAC   33.57 (+0.12%)
GILD   67.63 (+0.82%)
DIS   147.71 (+1.10%)
S&P 500   3,138.65 (+0.20%)
DOW   27,877.28 (-0.02%)
QQQ   204.39 (+0.24%)
AAPL   269.94 (+0.54%)
FB   200.74 (-0.06%)
MSFT   150.41 (-0.48%)
GOOGL   1,343.13 (+0.02%)
AMZN   1,743.17 (+0.23%)
CGC   20.66 (+2.84%)
NVDA   215.42 (+0.67%)
MU   48.65 (+2.51%)
BABA   201.73 (+0.64%)
GE   11.08 (+0.54%)
TSLA   354.78 (+1.70%)
T   38.11 (+0.13%)
AMD   39.29 (-0.41%)
ACB   2.57 (+1.98%)
F   9.10 (+0.33%)
PRI   135.17 (-0.08%)
NFLX   296.89 (+1.29%)
BAC   33.57 (+0.12%)
GILD   67.63 (+0.82%)
DIS   147.71 (+1.10%)
S&P 500   3,138.65 (+0.20%)
DOW   27,877.28 (-0.02%)
QQQ   204.39 (+0.24%)
AAPL   269.94 (+0.54%)
FB   200.74 (-0.06%)
MSFT   150.41 (-0.48%)
GOOGL   1,343.13 (+0.02%)
AMZN   1,743.17 (+0.23%)
CGC   20.66 (+2.84%)
NVDA   215.42 (+0.67%)
MU   48.65 (+2.51%)
BABA   201.73 (+0.64%)
GE   11.08 (+0.54%)
TSLA   354.78 (+1.70%)
T   38.11 (+0.13%)
AMD   39.29 (-0.41%)
ACB   2.57 (+1.98%)
F   9.10 (+0.33%)
PRI   135.17 (-0.08%)
NFLX   296.89 (+1.29%)
BAC   33.57 (+0.12%)
GILD   67.63 (+0.82%)
DIS   147.71 (+1.10%)
Log in

LON:CLL - Cello Health Share Price, Forecast & News

GBX 126.25
+0.75 (+0.60 %)
(As of 12/11/2019 09:49 AM ET)
Today's Range
125.87
Now: GBX 126.25
127
50-Day Range
125
MA: GBX 128.80
132.50
52-Week Range
98
Now: GBX 126.25
140.07
Volume41,164 shs
Average Volume46,452 shs
Market Capitalization£134.12 million
P/E Ratio17.78
Dividend Yield2.98%
BetaN/A
Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients. Read More…

Industry, Sector and Symbol

Industry Marketing Services
Sub-IndustryN/A
SectorServices
CUSIPN/A
CIKN/A
Phone+44-20-78128460

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£167.91 million
Cash FlowGBX 3.37 per share
Book ValueGBX 82.90 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£134.12 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CLL News and Ratings via Email

Sign-up to receive the latest news and ratings for CLL and its competitors with MarketBeat's FREE daily newsletter.


Cello Health (LON:CLL) Frequently Asked Questions

What is Cello Health's stock symbol?

Cello Health trades on the London Stock Exchange (LON) under the ticker symbol "CLL."

How often does Cello Health pay dividends? What is the dividend yield for Cello Health?

Cello Health declared a dividend on Wednesday, September 18th. Stockholders of record on Thursday, October 3rd will be given a dividend of GBX 1.15 per share on Friday, November 1st. This represents a dividend yield of 0.91%. The ex-dividend date is Thursday, October 3rd. The official announcement can be seen at this link. View Cello Health's Dividend History.

What price target have analysts set for CLL?

1 brokers have issued twelve-month target prices for Cello Health's stock. Their forecasts range from GBX 135 to GBX 160. On average, they anticipate Cello Health's stock price to reach GBX 147.50 in the next year. This suggests a possible upside of 16.8% from the stock's current price. View Analyst Price Targets for Cello Health.

What is the consensus analysts' recommendation for Cello Health?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cello Health in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cello Health.

Has Cello Health been receiving favorable news coverage?

Media headlines about CLL stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cello Health earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Cello Health.

Who are some of Cello Health's key competitors?

What other stocks do shareholders of Cello Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cello Health investors own include Lloyds Banking Group (LLOY), Optimer Pharmaceuticals (OPTR), Gilead Sciences (GILD), Sirius Minerals (SXX), Saga (SAGA), QinetiQ Group (QQ), Modern Water (MWG), IGAS Energy (IGAS), ICAP (IAP) and easyJet (EZJ).

Who are Cello Health's key executives?

Cello Health's management team includes the folowing people:
  • Mr. Mark Scott, CEO & Exec. Director (Age 53)
  • Mr. Mark Bentley, Group Fin. Director, Company Sec. & Exec. Director (Age 48)
  • Mr. Stephen Highley, Group COO & Director
  • Mr. Owen Williams, Managing Partner
  • Mr. Vincent Nolan, Managing Partner

How do I buy shares of Cello Health?

Shares of CLL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Cello Health's stock price today?

One share of CLL stock can currently be purchased for approximately GBX 126.25.

How big of a company is Cello Health?

Cello Health has a market capitalization of £134.12 million and generates £167.91 million in revenue each year. View Additional Information About Cello Health.

What is Cello Health's official website?

The official website for Cello Health is http://www.cellogroup.com/.

How can I contact Cello Health?

Cello Health's mailing address is 11-13 Charterhouse Buildings, LONDON, EC1M 7AP, United Kingdom. The company can be reached via phone at +44-20-78128460.


MarketBeat Community Rating for Cello Health (LON CLL)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  330 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  479
MarketBeat's community ratings are surveys of what our community members think about Cello Health and other stocks. Vote "Outperform" if you believe CLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel